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Alzheimer’s disease (AD) is a multifactorial neurodegenerative disease related to the deposition of aggregated amyloid-β (Aβ)
peptides in the brain. It has been proposed that metal ion dyshomeostasis and miscompartmentalization contribute to AD
progression, especially as metal ions (e.g., Cu(II) and Zn(II)) found in Aβ plaques of the diseased brain can bind to Aβ and
be linked to aggregation and neurotoxicity. The role of metal ions in AD pathogenesis, however, is uncertain. To accelerate
understanding in this area and contribute to therapeutic development, recent eﬀorts to devise suitable chemical reagents that
can target metal ions associated with Aβ have been made using rational structure-based design that combines two functions
(metal chelation and Aβ interaction) in the same molecule. This paper presents bifunctional compounds developed by two
diﬀerent design strategies (linkage or incorporation) and discusses progress in their applications as chemical tools and/or potential
therapeutics.
1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder that is a growing worldwide health concern
among aging populations [1, 2]. Attempts to unravel the
underlying causes of AD have been made across a variety
of disciplines, but despite the recognition of the physical
and mental symptoms of the disease, little is understood
about its etiology and pathological development [1–4]. It has
been established, however, that accumulated amyloid-β (Aβ)
plaques and neurofibrillary tangles are two of the defining
pathological characteristics of AD [1–4].
One of the currently accepted hypotheses of AD, the
amyloid cascade hypothesis, states that Aβ and its aggregated
formsmay cause the neurodegeneration observed in diseased
brains [1–7]. Aβ is a peptide (38–43 amino acids in length)
cleaved from the transmembrane amyloid precursor protein
(APP) by β- and γ-secretases [1, 3–7]. Once generated,
Aβ peptides can aggregate into oligomers, protofibrils, and
fibrils that adopt the well-organized β-sheet structure [1,
3, 4]. To date, the aggregation pathways and neurotoxicity
of Aβ have been extensively studied, but their involvement
in the pathology of AD remains elusive [1, 3, 4, 7–12].
Current evidence suggests that monomers and fibrils are
relatively benign, while soluble oligomers, including dimers,
are responsible for the neurotoxicity leading to dementia
[8, 9]. It also has been suggested that the formation of
amyloid plaques may be an eﬀect rather than a cause of
AD development, and further insight into the biological role
of Aβ may help elucidate this aspect [10–12]. Thus far, Aβ
has been identified as a causative agent in AD and ongoing
studies regarding the role of the Aβ peptide may contribute
to the establishment of a fundamental understanding of AD
neuropathogenesis.
Metal ion dyshomeostasis and miscompartmentaliza-
tion also are thought to play a significant part in the
progression of AD [1, 3, 4, 13–23]. The role of metal
ions, including their eﬀects on Aβ production/aggregation
and neurotoxicity, is a relevant but contentious topic in
the research field of AD. Particularly, Al, Fe, Cu, and Zn
have been found to be associated with Aβ plaques in the
brains of AD patients; however, like Aβ, how these metals
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participate in AD pathogenesis is still unclear [1, 3, 4, 13–
25]. It has been suggested that Al(III) can cause a change
in the Aβ conformation that stabilizes the oligomeric state
and increases surface hydrophobicity, which may cause an
increase in toxicity and membrane permeability [16, 19, 26].
The implication of Al(III) in AD has been debatable, as stud-
ies have been conducted using nonphysiological conditions
[16].
Recent interest in this field has focused on the association
of Fe(II/III), Cu(I/II), and Zn(II) with AD development
[1, 3, 4, 13–25]. Redox active Fe(II/III) and Cu(I/II)
bound to Aβ species can undergo Fenton chemistry lead-
ing to the generation of reactive oxygen species (ROS)
such as hydrogen peroxide and hydroxyl radical. ROS can
cause oxidative damage to biological molecules, which may
trigger neurodegeneration. An additional eﬀect of these
ions, especially Cu(II) and Zn(II), in the AD brain is
the facilitation of Aβ aggregation upon binding to the
peptide. Elevated concentrations of Cu(II) and Zn(II) have
been observed in senile plaques [1, 4, 13–15, 24, 25]; in
particular, high concentrations of labile zinc are found in
the regions of the brain most aﬀected by AD, the cortex
and hippocampus [4, 13–17, 19]. Although these metal
ions have been shown to be involved in Aβ aggregation
events, their direct interactions with the peptide are not
completely established. To understand metal coordination
properties of Aβ, structural investigations of metal-bound
Aβ species have been performed employing a wide range
of techniques such as nuclear magnetic resonance (NMR)
spectroscopy, electron paramagnetic resonance (EPR) spec-
troscopy, circular dichroism (CD) spectroscopy, and mass
spectrometry (MS) [3, 4, 18, 21, 22]. These studies have
suggested that the coordination of Cu(II) and Zn(II) in
Aβ species could occur via three histidine residues (H6,
H13, and H14) and possibly another N-terminal residue or
the peptide backbone. Structural characterization of metal
binding to Aβ is of great interest and has been reviewed
elsewhere [4, 18, 21, 22].
The involvement of metal ions in AD has been integrated
into the established amyloid cascade hypothesis to form
the “metal hypothesis of Alzheimer’s disease,” which states
that the interactions between metal ions and Aβ, as well as
abnormal metal ion homeostasis, are connected with AD
neuropathogenesis [3, 4, 13–23]. Based on this hypothesis,
disruption of metal-Aβ interactions via metal chelation
therapy has been proposed in order to reduce neurotoxicity
of metal-Aβ species and restore metal ion homeostasis
in the brain [1, 3, 4, 13, 15–17, 19, 27–35]. To date,
several chelators such as EDTA (N,N
′
-1,2-ethanediylbis[N-
(carboxymethyl)]glycine), clioquinol (CQ, 5-chloro-7-iodo-
8-hydroxyquinoline), and an 8-hydroxyquinoline derivative
(PBT2) have been utilized as agents for metal ion chelation
therapy in AD (Figure 1). Among these compounds, CQ and
PBT2 improved cognition in phase II clinical trials [30–33];
however, long-term use of CQ is limited by a side eﬀect,
subacute myelo-optic neuropathy [36]. Overall, the studies
using these and other traditional metal chelating agents
have exhibited modulation of metal-induced Aβ events
including aggregation and neurotoxicity in vitro and in vivo,
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Figure 1: Chemical structures of EDTA (N,N
′
-1,2-ethaned- iyl-
bis[N-(carboxymethyl)]glycine), clioquinol (CQ, 5-chloro-7-iodo-
8-hydroxyquinoline), and cyclen (cyc, 1,4,7,10-tetraazacyclododec-
ane).
which suggests that the continued development of metal ion
chelation therapy is a valuable pursuit for AD.
To obtain a greater understanding of the role of metal
ions associated with Aβ and fashion potential therapeu-
tic agents for AD, improvement upon the metal ion
chelation therapy approach would be desirable. Current
eﬀorts have been to apply rational structure-based design
toward construction of small molecules that are capable
of synergistically recognizing both metal ions and Aβ [4,
37–42]. This approach could improve the limitations of
the traditional metal chelating compounds (e.g., nonspe-
cific metal chelation and low blood-brain barrier (BBB)
permeability). The reported small molecules that have
bifunctionality (metal chelation and Aβ interaction) are
hybrids of a metal chelation moiety like EDTA, CQ,
or cyclen (cyc, 1,4,7,10-tetraazacyclododecane) (Figure 1)
and a known Aβ interaction scaﬀold, including ThT, the
KLVFF peptide, curcumin, IMPY, and p-I-stilbene (ThT
= thioflavin-T, 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-
benzothiazolium; curcumin = (1E,6E)-1,7-bis(4-hydroxy-
3-methoxyphenyl)-1,6-heptadiene-3,5-dione; IMPY = 4-(7-
iodoimidazo[1,2-a]pyridin-2-yl)-N,N-dimethylaniline; p-I-
stilbene = N,N-dimethyl-4-[(1E)-2-(4-iodophenyl)ethen-
yl]benzenamine) (Figure 2) [4, 37–42]. Bifunctional small
molecules targeted to metal ions surrounded by Aβ species
have been developed following two diﬀerent design prin-
ciples (Figure 3, Approach I: linkage of metal chelation
and Aβ interaction structural components; Approach II:
incorporation of a metal-binding site into an Aβ interacting
framework). The capability of these bifunctional compounds
to regulate metal-Aβ-involved events such as aggregation
and neurotoxicity in vitro and in vivo is promising for
further applications. The progress to date in the design and
utilization of these compounds is discussed herein.
2. Approach I: Linked Compounds
The “linked” compounds are those in which a structural
moiety for metal binding is connected to an Aβ interacting
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Figure 2: Chemical structures of ThT (thioflavin-T), a neutral ThT derivative, Pittsburgh Compound B, the KLVFF peptide,
curcumin, IMPY, and p-I-stilbene (ThT = 2-[4-(dimethylamino)phenyl]-3,6-dimethylbenzothiazolium; neutral ThT derivative = 2-
(4-(dimethylamino)phenyl)-6-methylbenzothiazole; Pittsburgh Compound B = 2-[4-(methyl-11C-amino)phenyl]-6-benzothiazolol; cur-
cumin = ((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; IMPY = 4-(7-iodoimidazo[1,2-a]pyridin-2-yl)-N,N-
dimethylaniline; p-I-stilbene = N,N-dimethyl-4-[(1E)-2-(4-iodophenyl)ethenyl]benzenamine).
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Figure 3: Overview of the two rational structure-based design
strategies currently used to develop small molecules having bifunc-
tionality (metal chelation and Aβ interaction). The first approach
is based on the connection of metal chelation and Aβ recognition
structural moieties (Approach I: linkage). The second approach is
direct incorporation of a metal chelation site into an Aβ interacting
framework (Approach II: incorporation).
molecule (Approach I, Figure 3). The linked bifunctional
moleculesXH1(N,N-bis[2-[[2-[[4-(2-benzothiazolyl) phen-
yl]amino]-2-oxoethyl](carboxymethyl)amino]ethyl]glycine),
cyc-KLVFF, and cyc-Curcumin are discussed in this paper
(Figure 4) [4, 37–40].
2.1. XH1. One of the small molecules most frequently used
to understand Aβ aggregation pathways is ThT (Figure 2)
[43–46]. Due to the ability of ThT to selectively bind to
aggregated amyloid forms and thereby generate a fluores-
cence response, it can be employed to monitor the degree
of Aβ aggregation. It has been proposed that ThT could
be a useful framework to pursue in the development of Aβ
imaging agents [47]. The application of ThT as a chemical
probe in vivo, however, is limited by its positive charge,
which impairs its ability to diﬀuse through the BBB [47–49].
Neutral ThT derivatives (Figure 2) prepared to alleviate this
limitation of ThT exhibited more favorable properties, such
as 600-fold higher lipophilicity and greater binding aﬃnity
to Aβ [47]. These compounds also adhere to the restrictive
terms of Lipinski’s rules (low molecular weight (MW ≤
450), relatively lipophilic (c logP, calculated logarithm of
the octanol/water partition coeﬃcient, ≤5), hydrogen-bond
donor atoms (HBD ≤ 5), hydrogen-bond acceptor atoms
(HBA ≤ 10), and small polar surface area (PSA ≤
90 A˚2)), which, along with the calculated logBB, can be used
to predict BBB permeability [48, 49]. The modifications
of the neutral ThT derivatives have been conducted to
devise applicable in vivo imaging agents. One of the most
successful examples has been the preparation and utilization
of a carbon-11-labeled compound, Pittsburgh Compound
B (Figure 2), as an agent for positron emission tomography
(PET) [47, 50, 51]. This compound has shown high aﬃnity
for Aβ, specificity for staining plaques, and good brain
entry and clearance. Overall, the ThT scaﬀold is an ideal
candidate for chemical modification in order to produce new
bifunctional molecules capable of targeting metal-Aβ species
(vide infra).
Dedeoglu et al. were the first to report a neutral ThT-
conjugated EDTA derivative, XH1 (Figure 4), for metal-
associated Aβ species [39]. Computational ligand/receptor
docking studies using XH1 indicated its specific interactions
with Aβ1−40. XH1 was able to decrease Zn(II)-induced
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Figure 4: Chemical structures of small molecules XH1 (N,N-bis[2-[[2-[[4-(2-benzothiazolyl)phenyl]amino]-2-oxoethyl](carboxymethyl)
amino]ethyl]glycine), cyc-KLVFF, and cyc-Curcumin that were designed by Approach I (Figure 3).
Aβ1−40 aggregation as well as APP expression in human SH-
SY5Y neuroblastoma cells, indicating the possible modifica-
tion of metal-Aβ interactions by XH1. Given these positive
results in vitro and no significant neurotoxicity at low
micromolar concentrations in living cells, XH1 was tested
further in the presenilin 1 (PS1)/APP transgenic mice model.
While no behavior diﬀerences were observed in mice treated
with XH1 for four weeks compared to those untreated,
the deposition of Aβ plaques and the concentration of
cortical Aβ were reduced in the treated mice. Therefore,
these observations suggest that XH1 may be BBB permeable.
Overall, the Aβ interaction and nontoxic nature of XH1
are a promising beginning for designing a new class of
bifunctional small molecules.
2.2. Cyc-KLVFF. “β-sheet blockers” that interfere with amy-
loidogenesis by interacting with the portions of the peptide
responsible for facilitating self-aggregation have been inves-
tigated [52–56]. The peptide sequence containing residues
16–20 (KLVFF) from the full-length peptide has been found
to be the most eﬀective at hindering Aβ fibrillogenesis.
A bifunctional small molecule, cyc-KLVFF (Figure 4), was
fashioned by the coupling of the KLVFF peptide as the
amyloid recognition moiety with the metal chelator cyclen
(Figures 1 and 2) [40]. Cyclen is a macrocyclic metal chelator
that can modulate Aβ aggregation and neurotoxicity in vitro
and in cortical neuronal cells of C57BL6/J mice, and it has
been shown that cyclen-Co(III) complexes have proteolytic
activity [57, 58]. Cyc-KLVFF (Figure 4) was eﬀective toward
reducing metal-triggered Aβ aggregation and neurotoxicity
including Cu(II)-induced ROS production in vitro and in
neuronal cell culture [40]. Aggregated forms of the peptide
also were cleaved upon incubation with cyc(Cu(II))-KLVFF
complex. Apo-cyc-KLVFF was nontoxic in primary mouse
N2a neuroblastoma cells and could recover the toxicity of
Aβ1−42 in cells pretreated with Cu(II). These results indicate
the potential of apo-cyc-KLVFF to sequester Cu(II) from
heterogeneous environments to protect against metal-Aβ
events. Cyc-KLVFF potentially is limited by nonspecific
cleavage of other Cu-containing proteins while BBB per-
meability may present an additional challenge due to the
high MW of the compound [40, 48, 49]. Taken together,
the design and studies of cyc-KLVFF suggest that the linkage
of two structural frameworks for Aβ interaction and metal
chelation (Approach I, Figure 3) could enhance reactivity
toward metal-Aβ species.
2.3. Cyc-Curcumin. Curcumin (Figure 2) has shown anti-
amyloidogenic, antioxidative, and anti-inflammatory prop-
erties [59–61]. The structure-activity relationships of Aβ
aggregation inhibitors based on curcumin have been studied,
and three necessary structural features were identified: the
presence of two terminal aromatic groups, the substitution
of these aromatics, and the length and flexibility of the
linker between the aromatic groups [62]. The reported
properties of curcumin could aﬀord a strong prototype
recognition framework to incorporate into new bifunc-
tional small molecules. Another bifunctional small molecule
containing cyclen, cyc-Curcumin (Figure 4), was prepared
to evaluate the ability of other recognition frameworks to
function in this platform [40]. The corresponding metal
complex, cyc(Cu(II))-Curcumin, presented Aβ aggregation
inhibition and Aβ cleavage activity similar to cyc(Cu(II))-
KLVFF. The cyc(Cu(II))-Curcumin complex showed modest
rescue of Aβ-induced neurotoxicity. This compound demon-
strates that linking a nonpeptide Aβ recognition/interaction
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molecule to a metal chelation framework may exert a similar
eﬀect on Aβ aggregation pathways, introducing another
avenue to develop bifunctional compounds targeted to
metal-Aβ species following Approach I.
3. Approach II: Incorporated Compounds
The second class of bifunctional small compounds reviewed
herein was designed based on direct incorporation of a
metal-binding site into the structural framework of an Aβ
recognition/interaction molecule (Approach II, Figure 3).
Utilizing Approach II, three categories of compounds have
been reported: (a) the ThT-based molecules, HBX,HBT, BM,
and their iodinated derivatives (HBX = 2-(2-hydroxyphenyl)
benzoxazole; HBT = 2-(2-hydroxyphenyl)benzothiazole; BM
= 2-(2-aminophenyl)benzimidazole), (b) the IMPY deriva-
tive (1) (1 = 2-[4-(dimethylamino)phenyl]imidazo[1,2-a]
pyridine-8-ol), and (c) the stilbene derivative (2) (2 =
N1,N 1-dimethyl-N4-(pyridin-2-ylmethylene)benzene-1,4-
diamine) (Figure 5) [37, 38, 41, 42].
3.1. ThT Derivatives. The neutral ThT derivative (Figure 2)
was used as a framework for designing bifunctional small
molecules studied by Rodrı´guez-Rodrı´guez et al. [41]. By
virtual screening of commercially available neutral ThT
derivatives containing a bidentate metal chelation site, small
molecules that could target metal ions surrounded by
Aβ were identified. The criteria applied to select desired
compounds required that their structures could be iodinated
and satisfy the restrictive terms of Lipinski’s rules, along
with logBB [41, 48, 49]. Their virtual screen identified 36
candidates, which were narrowed to three small molecules,
HBX, HBT, and BM (Figure 5(a)). The iodinated ver-
sions of these three compounds, HBXI, HBTI, and BMI
(Figure 5(a)), also were prepared and investigated due to
their potential contribution to the development of new
SPECT imaging agents (SPECT = single photon emission
computed tomography).
HBXI and HBTI were found to be primarily neutral
at physiological pH (e.g., 7.4), which indicates potential
BBB permeability in vivo while BMI existed in both the
protonated and neutral forms at this pH [41]. The solution
speciation studies regarding the binding aﬃnities of Cu(II)
and Zn(II) to these compounds suggest their capability
to sequester metal ions associated with soluble forms of
Aβ. Inhibition of both Cu(II)- and Zn(II)-induced Aβ
aggregation was most significant for HBTI, while HBXI
and BMI showed a similar eﬀect only for Cu(II)-triggered
Aβ aggregation. Also, fluorescence measurements were con-
ducted to assess the possible use of HBX, HBT, and their
iodinated analogues as potential in vivo biomarkers for
amyloid aggregates. Promisingly, HBX and HBT exhibited
stronger fluorescence responses with mature amyloid fib-
rils than Pittsburgh Compound B, used in clinical trials.
HBXI and HBTI demonstrate the potential for improving
radioisotopic detection of Aβ aggregates in the human brain
[41]. Taken together, the studies using small, neutral ThT
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Figure 5: Chemical structures of small molecules (a) HBX/HBXI,
HBT/HBTI, and BM/BMI, (b) 1, and (c) 2 that were constructed
employing Approach II (Figure 3) (HBX = 2-(2-hydroxyphenyl)
benzoxazole; HBT = 2-(2-hydroxyphenyl)benzothiazole; BM =
2-(2-aminophenyl)benzimidazole; 1 = 2-[4-(dimethylamino)phe-
nyl]imidazo[1,2-a]pyridine-8-ol; 2 = N1,N1-dimethyl-N4-(pyri-
din-2-ylmethylene)benzene-1,4-diamine).
derivatives suggest that bifunctional small molecules could
have multiple applications in AD diagnosis and therapy.
3.2. IMPY Derivative. The need for in vivo Aβ plaque
imaging molecules also has led to the development of a
ThT analogue, IMPY (Figure 2) [63–68]. This radiolabeled
iodinated ligand can be a useful SPECT reagent over some
current PET probes for a number of reasons including
practicality of administering the compound as well as cost
and availability of SPECT equipment in clinical settings
[64–66]. IMPY binds to Aβ1−40 aggregates with nanomolar
aﬃnity and likely occupies a similar binding site as the
thioflavin dyes due to its planarity and hydrophobicity. IMPY
also has shown favorable pharmacokinetic properties in the
Tg2576 and PS1/APP transgenic mouse models as well as
safety in human patients [64–66]. The studies performed
thus far illustrate the promise of radiolabeled IMPY as an in
vivo SPECT imaging agent for potential diagnosis of AD in
human patients.
The positive outcomes from studies with IMPY suggest
that the modification of this framework to include a metal
chelation site could be eﬀective for developing bifunctional
small molecules toward metal ions associated with Aβ. One
bifunctional IMPY derivative, 1, has been reported by Lim
and coworkers (Figure 5(b)) [42]. An OH functionality was
incorporated into the core framework of IMPY to generate
a metal chelation site. Additionally, the structure fulfills
the criteria of the restrictive terms of Lipinski’s rules and
the logBB values, indicating that it may be drug-like and
BBB permeable [48, 49]. Along with metal-binding studies
of 1 by UV-visible spectroscopy, two-dimensional (2D)
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1H-15N TROSY-HSQC NMR spectroscopy was employed
in order to understand the interaction of 1 with Aβ1−40
monomer (TROSY = transverse relaxation optimized spec-
troscopy; HSQC = heteronuclear single quantum correla-
tion). Changes in the shifts of the NMR spectrum indicated
that 1 interacts with Aβ residues including E11 and H13.
Based on the close proximity of these residues to the metal
chelation site (H6, H13, and H14) [3, 4, 18, 21, 22], 1
could possibly interact with metal ions in that portion of
the peptide. This implies that 1 may have the potential
to block Aβ fibrillogenesis from the monomeric state via
disruption of metal-Aβ interactions. Compared with the
traditional metal chelators CQ, phen (1,10-phenanthroline),
and EDTA, 1 more eﬀectively inhibited Cu(II)-triggered
Aβ aggregation and disassembled Cu(II)-associated Aβ
aggregates [42]. Furthermore, 1 was able to modulate
ROS generated by Cu-Aβ species. Although this compound
showed cytotoxicity in human neuroblastoma cells at low
micromolar concentrations, the favorable reactivity toward
Cu(II)-associated Aβ aggregation pathways warrants further
chemical modifications of the IMPY scaﬀold for serving in
future investigations.
3.3. Stilbene Derivative. Stilbene derivatives (Figure 2) have
been widely devised and used as imaging agents for amyloid
plaques [69–71]. Overall, stilbene derivatives are small,
simple structures that could be labeled easily for in vivo
imaging applications. While trans-stilbene has low aﬃnity
for Aβ aggregates, derivatives that contain electron-donating
functionalities such as p-N(CH3)2, p-OCH3, or p-OH groups
bind to Aβ with higher aﬃnity. These characteristics have
made it an exemplar framework to modify for construction
of bifunctional molecules. Thus, Hindo et al. have recently
reported a stilbene derivative (2, Figure 5(c)) containing two
N donor atoms as a bidentatemetal chelation site [42]. Based
on the restrictive terms of Lipinski’s rules and the calculated
logBB value, 2 satisfies the requirements for potential BBB
permeability [48, 49].
The stilbene derivative, 2, presented encouraging reactiv-
ity toward metal-Aβ species [42]. This molecule was shown
to interact with Cu(II) studied by UV-visible spectroscopy
and the interaction of the compound with Aβ1−40 monomer
was investigated using 2D 1H-15N TROSY-HSQC NMR
spectroscopy. Similar to 1, upon addition of 2 to the peptide
solution, the residues E11 and H13 were most significantly
shifted, which suggests close contact of 2 with the metal-
binding site in Aβ. The bifunctional compound 2 not only
controlled Cu(II)-induced formation of Aβ aggregation but
also disaggregated preformed Cu(II)-treated Aβ aggregates.
In addition, this compound attenuated ROS formation
by Cu-Aβ species, indicated no cytotoxicity up to high
micromolar concentrations, and, more importantly, was
capable of diminishing neurotoxicity of Cu-Aβ species in
human neuroblastoma cells. Though 2 has shown promising
results thus far, the instability of this compound in aqueous
media due to the susceptibility of the imine functionality
to hydrolysis would hinder its in vivo applications. There-
fore, structural modifications of 2 will lead to the next
generation of biologically compatible small molecules as
chemical tools and/or potential therapeutic agents for AD
[72].
4. Conclusion
Metal ions associated with Aβ have been suggested to be
related to AD neuropathogenesis; however, the detailed
mechanisms are not fully understood. To elucidate the
role of metal ions surrounded by Aβ and eventually to
diagnose, treat, and prevent AD, small molecules that
have bifunctionality (metal chelation and Aβ interaction)
have been designed as chemical tools and/or potential
therapeutic agents based on the two rational structure-
based design strategies. The first approach involves linking
two structural components for metal chelation and Aβ
interaction. According to this approach, XH1, cyc-KLVFF,
and cyc-Curcumin were constructed by combining the Aβ
recognition/interaction molecules (ThT, the KLVFF peptide,
or curcumin) with metal chelation moieties (EDTA or
cyclen). The second approach represents direct incorpora-
tion of N and/or O donor atoms for metal chelation into
Aβ interacting frameworks (ThT, IMPY, or p-I-stilbene)
producing HBX/HBXI, HBT/HBTI, BM/BMI, 1, and 2. The
bifunctional compounds described in this paper have shown
promising preliminary results toward metal-induced Aβ
aggregation and neurotoxicity in vitro and/or in vivo; how-
ever, comprehensive in vivo studies of these molecules would
be valuable. Common challenges of developing eﬀective
small molecules in biological systems (in particular, in the
brain) include optimization of BBB permeability, stability,
and toxicity in order to accomplish their future applications.
Overall, the bifunctional small molecules discussed herein
have laid a foundation for the emerging field of rational
structure-based design of small molecules for targeting metal
ions surrounded by Aβ species and regulating metal-involved
Aβ events. Future endeavors in this area will provide inspira-
tion for uncovering details of the roles of metal-Aβ species in
AD neuropathogenesis and may oﬀer insight into the appli-
cability to and understanding of other neurodegenerative
diseases.
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